Abstract: The invention relates to new forms of salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.
Abstract: The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.
Type:
Grant
Filed:
August 5, 2008
Date of Patent:
October 2, 2012
Assignee:
Novartis AG
Inventors:
Erwin Marti, Hans R Oswald, Peter Bühlmayer, Wolfgang Marterer
Abstract: The present invention relates to a compound The instant invention relates to a compound of formulae (I A), (I B), (X A), (X B), (Y A) or (Y B), wherein R? represents and R? represents hydrogen, hydroxy, C1-C7alkoxy, C1-C8-alkanoyloxy, or R5R4N—CO—O—, where R4 and R5 independently are C1-C7alkyl or phenyl which is unsubstituted or substituted by a substitutent selected from C1-C7alkyl, C1-C7alkoxy, halogen and trifluoromethyl and where R4 additionally is hydrogen; or R4 and R5 together represent C3-C6alkylene; in free form or in form of a pharmaceutically acceptable acid addition salt. Compounds of formulae (I A), (I B), (X A), (X B), (Y A) or (Y B) inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.
Abstract: The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseases.
Abstract: The invention relates to a method or process for the manufacture of blood pressure lowering agents, such as valsartan, novel intermediates as well as process steps in said synthesis. The method or process leads via the novel intermediate salts of the formula IA, or a tautomer thereof, wherein [kat]n+ is a cation and n is 1, 2, 3, 4, 5 or 6.
Type:
Grant
Filed:
July 10, 2006
Date of Patent:
June 1, 2010
Assignee:
Novartis AG
Inventors:
Gottfried Sedelmeier, Dominique Grimler
Abstract: The present invention relates to a process for the manufacture of intermediates that may be used for the manufacture of ARBs (also called angiotension II receptor antagonists or AT1 receptor antagonists) comprising as a common structural feature a (1H-tetrazol-5-yl)-biphenyl ring.
Abstract: The present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients (i) an AT1-receptor antagonist or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or (b) an insulin sensitizer or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier.
Abstract: The invention relates to the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of acute MI and for the secondary prevention of acute MI.
Type:
Grant
Filed:
June 3, 2004
Date of Patent:
July 14, 2009
Assignee:
Novartis AG
Inventors:
Jessica M Mann, Pascale Oddou, Eric M Neuhart
Abstract: A process for the preparation of polymorph Form I of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine, or olanzapine.
Type:
Grant
Filed:
May 30, 2003
Date of Patent:
November 20, 2007
Assignee:
Sandoz, Inc.
Inventors:
Hiren V. Patel, Anup K. Ray, Pramod B. Patel, Mahendra R. Patel
Abstract: Cefuroxime in the form of a salt with n-butylamine; and its use for the production of cefuroxime axetil or for the production of the sodium salt of cefuroxime.
Abstract: The invention relates to plants, seeds and DNA constructs containing DNA that is either SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or the complementary or double stranded sequence thereof, as well as a method for their preparation.
Abstract: A spray booth is provided for reproducible application of agrichemicals to plants. The spray booth comprises a support member for supporting a plurality of plants, a cover having a plurality of sides and a top and forming an enclosure with the support member for enclosing the plants therein, an agrichemical source for providing a pressurized agrichemical, and a spray arm having a spray mechanism operably connected to the agrichemical source. Preferably, the spray arm is disposed within the enclosure and over the support member such that it extends across the width of the support member. The spray mechanism is used for spraying a predetermined amount of the agrichemical therefrom in the form of a fine mist along the length of the spray arm. Advantageously, at least one of the support member and the spray arm is laterally moveable relative to the other such that the plants disposed both lengthwise and widthwise on the support member are substantially uniformly misted with the agrichemical.
Abstract: Novel halo-N-substituted urea compounds and pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel halo-N-substituted urea compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammals such as a human.
Abstract: A method for preparing transgenic plants and seeds is claimed. The method is particularly useful for high-throughput transformation of plants, such as Arabidopsis thaliana, using many different types of DNA sequences of interest.
Abstract: This invention relates to plants, seeds and DNA constructs containing DNA that is either SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:20, or the complementary or double stranded sequence thereof, as well as a method for their preparation.
Abstract: The invention is directed to methods and compositions for the determination of deoxyxylulose 5-phosphate synthase (DXPS) activity. The methods and compositions of the invention are amenable to high-throughput screening assays for the identification of inhibitors and enhancers of DXPS activity. Such compounds have use in the modulation of plant and microbial growth. The compositions of the invention are DXPS fragments and chimeric polypeptides that have increased solubility as compared to the wild-type DXPS polypeptide. These DXPS fragments and chimeric polypeptides can be recombinantly expressed and purified in quantities suitable for high-throughput screening assays. The assays of the invention are based on the detection of substrates of DXPS that remain after a DXPS reaction.
Type:
Grant
Filed:
July 27, 2000
Date of Patent:
December 4, 2001
Assignee:
Paradigm Genetics, Inc.
Inventors:
John W. Rice, Andreas S. Kloti, John M. Crawford, Jr., Beth Lanning, Sandy J. Stewart
Abstract: A process for recovering a lipophilic oligosaccharide antibiotic from an aqueous fermentation broth containing the lipophilic oligosaccharide antibiotic admixed with impurities, by-products and/or suspended solids, comprising:
a) combining said fermentation broth with an adsorbent;
b) adjusting the pH of the broth to alkaline in order to solubilize the antibiotic in the broth;
c) allowing sufficient time for the solubilized antibiotic in the alkaline broth to be adsorbed by the adsorbent;
d) adjusting the pH of the broth to about neutral in order to stabilize the antibiotic adsorbed on the adsorbent; and
e) separating the adsorbent to which the antibiotic is adsorbed from the broth.
A medium for storing an oligosaccaride antibiotic comprising an adsorbent having a lipophilic oligosaccaride antibiotic adsorbed thereon is also disclosed.
Type:
Grant
Filed:
December 6, 1999
Date of Patent:
November 20, 2001
Assignee:
Schering Corporation
Inventors:
Yair Alroy, Steven Blaisdell, Allan Morenberg, Schaefer Eugene
Abstract: The invention relates to DNA which encodes Arabidopsis 1-deoxy-xylulose-5-phosphate reductoisomerase and to a method of identifying modulators of the 1-deoxy-D-xylulose-5-phosphate reductoisomerase and 1-deoxy-D-xylulose-5-phosphate synthase activity.
Type:
Grant
Filed:
November 24, 1999
Date of Patent:
October 16, 2001
Assignees:
Paradigm Genetics, Inc. R.T.P, Bayer Ag
Inventors:
William Frank Martin, Ruediger Hain, Klaus-Guenther Tietjen, Marco Busch, Andreas S. Kloti
Abstract: A colored, sunscreen emulsion is disclosed which employs a water-soluble dye or a blend of water-soluble dyes whose color substantially disappears when the sunscreen emulsion dries after it is spread on the skin and/or is rubbed out. The coloration in the sunscreen enables the user to more effectively protect against sunburn by allowing more complete and uniform coverage of the sunscreeen on the skin.
Type:
Grant
Filed:
November 24, 1997
Date of Patent:
September 18, 2001
Assignee:
Schering-Plough HealthCare Products, Inc.
Abstract: A colored, sunless tanning emulsion is disclosed which employs a water-soluble dye or a blend of water-soluble dyes whose color substantially disappears when the sunless tanning emulsion dries after it is spread on the skin and/or is rubbed out.
Type:
Grant
Filed:
November 24, 1997
Date of Patent:
July 17, 2001
Assignee:
Schering-Plough HealthCare Products, Inc.
Inventors:
Inna Karpov, Elaine M. Morefield, Jamie S. Ross